A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/14/2006	US20060281694 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents; treatment of gingivitis; platelet aggregation modulation
12/14/2006	US20060281693 Renal function improvement
12/14/2006	US20060281692 Administering 1-(4-beta-D-glucopyranosyloxybenzyl)-2-isobutyltartrate (Coelovirin A), scopolamine, cycloheximide, and/or amyloid precursor proteins; frog orchid extracts; for improving memory performance; Alzheimer's disease; high activity, low toxicity and no inhibition to cholinesterase
12/14/2006	US20060281691 Method of treating obesity
12/14/2006	US20060281689 Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
12/14/2006	US20060281688 Administration of HCV protease inhibitors in combination with food to improve bioavailability
12/14/2006	US20060281686 Aza-peptides
12/14/2006	US20060281682 Methods and compositions for the treatment of gastrointestinal disorders
12/14/2006	US20060281679 Human FGF-23 gene and gene expression products
12/14/2006	US20060281677 Compositions and methods for intracellular delivery of biotinylated cargo
12/14/2006	US20060281666 Substitute thiophenes and uses therof
12/14/2006	US20060281154 Enzymatic depolymerisation of carboxymethylcellulose in hydroalcoholic solutions
12/14/2006	US20060281152 Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
12/14/2006	US20060281146 Novel compositions and methods for the treatment of immune related diseases
12/14/2006	US20060281130 Metod of modulation of interaction between receptor and ligand
12/14/2006	US20060281095 44 human secreted proteins
12/14/2006	US20060281081 Method of diagnosing colon and gastric cancers
12/14/2006	US20060281072 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy
12/14/2006	US20060281071 Stearoyl-CoA desaturase assay
12/14/2006	US20060280819 Ellagic acid food supplement prepared from pomegranate seed
12/14/2006	US20060280816 Efficient method for producing compositions enriched in total phenols
12/14/2006	US20060280815 Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite
12/14/2006	US20060280814 Nutritional composition for increasing creatine uptake in skeletal muscle
12/14/2006	US20060280812 Compositions and methods for the treatment of muscular dystrophy
12/14/2006	US20060280811 Formulations for the treatment of arthritis conditions
12/14/2006	US20060280810 Disinfecting teat care compositions
12/14/2006	US20060280809 Anti-infective iodine based compositions for otic and nasal use
12/14/2006	US20060280800 Tanaproget compositions containing ethinyl estradiol
12/14/2006	US20060280794 Solid pharmaceutical preparation
12/14/2006	US20060280793 Oral sustained-release preparation of fasudil hydrochloride
12/14/2006	US20060280791 Pharmaceutical formulations
12/14/2006	US20060280790 Pharmaceutical formulations
12/14/2006	US20060280789 Sustained release formulations
12/14/2006	US20060280788 Delivery and formulations of mast cell stabilizers
12/14/2006	US20060280784 amphiphilic substance or a hydrophobic substance is modified with a glycerol derivative, which is useful as a surface modifier for producing a drug carrier; liposome, a fat emulsion, an emulsion, a micell and a fine particle crystal
12/14/2006	US20060280777 Encapsulated energy gel compositions
12/14/2006	US20060280776 Diet food
12/14/2006	US20060280774 Compositions and methods for treating glaucoma
12/14/2006	US20060280771 Drug delivery system
12/14/2006	US20060280765 Navel orangeworm pheromone composition
12/14/2006	US20060280761 Nanofluidized B-12 composition and process for treating pernicious anemia
12/14/2006	US20060280746 (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents
12/14/2006	US20060280742 monoclonal antibody for treating cancer, neovascularization, vascular and arthritic diseases; immunoassay; immunotherapy; inhibition or antagonism of TNF decreases expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF); decrease angiogenesis
12/14/2006	US20060280738 Anti-CD19 antibody therapy for transplantation
12/14/2006	US20060280730 Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels
12/14/2006	US20060280723 Interferon for treating or preventing a coronaviral infection
12/14/2006	US20060280721 Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
12/14/2006	US20060280720 Diisocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant
12/14/2006	US20060280719 An addition polymer from an unsaturated monomer containing a phosphonate group and a phosphinate group separated from eachother by an optionally fluorinated methylene group; treatment of hyperphosphotemia, chronic renal failure, hyperparathyroidism, uremic bone disease, or osteoporosis
12/14/2006	US20060280718 Compositions and methods for treating pain
12/14/2006	US20060280715 Retinoid solutions and formulations made therefrom
12/14/2006	US20060280711 Process for treating marionette lines
12/14/2006	US20060280703 Antimycotic nail varnish
12/14/2006	US20060280692 A condensation aerosol for delivery of olanzapine by heating a compositionof olanzapine coated on a solid support to vaporize and condense; the vapor comprising particles of >10 percent by weight of olanzapine and <5 percent by weight of olanzapine degradation products; aerodynamic diameter=<5 microns
12/14/2006	DE202005012015U1 Hydrogel, useful in wound filler and wound dressing, comprises at least gel-forming polysaccharide, at least one acrylic acid derivative and an electrolyte mixture of at least two different electrolytes
12/14/2006	DE102005027170A1 New substituted tetrahydroquinoline compounds are mitotic motor-protein Eg5 modulators useful to treat or prevent e.g. cancer, glioblastoma, lymphatic leukemia, arteriosclerosis, eye disease, diabetic retinopathy and arthritis
12/14/2006	DE102005027169A1 Tetrahydrochinolinderivate Tetrahydroquinoline
12/14/2006	DE102005027168A1 Tetrahydrochinoline Tetrahydroquinolines
12/14/2006	DE102005026809A1 Benzothiazol-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen Benzothiazol-2-one derivatives as inhibitors of lipases, and phospholipases
12/14/2006	DE102005026808A1 Benzooxazol-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen Benzooxazol-2-one derivatives as inhibitors of lipases, and phospholipases
12/14/2006	DE102005026231A1 Peptid-Deformylase (PDF) Inhibitoren 3 Peptide deformylase (PDF) inhibitors 3
12/14/2006	DE102005026223A1 Stabile Hemicellulose-Paste, Verfahren zu deren Herstellung und deren Verwendung Hemicellulose-stable paste, process for their preparation and their use
12/14/2006	DE102005026051A1 Mixture, useful in photodynamic therapy as photosensitizer and/or fluorescence active substance, comprises chlorin e6 derivatives and pyrrolidone derivatives
12/14/2006	DE102005025855A1 Verfahren zur Herstellung von pulverförmigen Alkoxycarbonylaminotriazin A process for the preparation of pulverulent alkoxycarbonylaminotriazine
12/14/2006	DE102005024040A1 Kosmetisches oder therapeutisches Kombinationspräparat mit Theanin Cosmetic or therapeutic combination product with theanine
12/14/2006	DE102005019549A1 Cosmetic/dermatological preparation, useful to prevent and/or treat e.g. inflammatory skin conditions and/or skin protection by sensitive determination, symptoms of UV radiation damage on the skin, comprises a diaminobenzimidazol
12/14/2006	DE102005014936A1 New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders
12/14/2006	DE102005009194B4 Verfahren zur Herstellung von polymorph stabilem Triamcinolonacetonid A process for producing polymorphic stable triamcinolone acetonide
12/14/2006	CA2820200A1 Compositions and methods for enhancing nitric oxide delivery
12/14/2006	CA2620986A1 3 -aryloxy- 8 -aza-bicyclo [3.2.1.] oct- 6- ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/14/2006	CA2614295A1 Transcription factor decoy
12/14/2006	CA2611731A1 Indane derivatives as modulators of ion channels
12/14/2006	CA2611724A1 Stabilized milnacipran formulation
12/14/2006	CA2611720A1 Methods and compositions for the treatment of ocular disorders
12/14/2006	CA2611713A1 Treatment of sleep-wake disorders
12/14/2006	CA2611609A1 Ampa receptor potentiators
12/14/2006	CA2611608A1 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof
12/14/2006	CA2611451A1 Solid preparation
12/14/2006	CA2611450A1 Method for producing polymerized coordination compounds of platinum complex
12/14/2006	CA2611445A1 Method for evaluation of compound using rsk1
12/14/2006	CA2611435A1 Novel triterpenic acid derivative and preparation for external application for skin comprising the same
12/14/2006	CA2611430A1 Pharmaceutical compositions of a neuroactive steroid and uses thereof
12/14/2006	CA2611401A1 Oxindoles as kinase inhibitors
12/14/2006	CA2611391A1 Angiogenesis inhibitors
12/14/2006	CA2611312A1 Organic compounds
12/14/2006	CA2611261A1 Crystal of salt of benzimidazole compound
12/14/2006	CA2611201A1 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
12/14/2006	CA2611140A1 Compositions and methods for enhancing nitric oxide delivery
12/14/2006	CA2611083A1 Production of solid solutions based on poorly-soluble active substances by a short-term heating and rapid drying
12/14/2006	CA2611011A1 Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
12/14/2006	CA2610977A1 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	CA2610975A1 Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	CA2610956A1 Improved treatment for anemia using a hif-alpha stabilising agent
12/14/2006	CA2610881A1 Eye drop containing roflumilast
12/14/2006	CA2610866A1 Compositions for treating sleep-related breathing disorders comprising cholecystokinin (cck) receptor antagonists
12/14/2006	CA2610860A1 Pharmacological chaperones for treating obesity
12/14/2006	CA2610802A1 Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy
12/14/2006	CA2610800A1 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
12/14/2006	CA2610795A1 3-arylidene-anabaseine compounds as alpha 7 nicotitnic receptor selective ligands
12/14/2006	CA2610792A1 Synthesis of glycerolipid carbamates and dicarbamates and their use as antitumor compounds

1 ... 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 3980 3981 3982 3983 3984 3985 3986 3987 ... 7860